WINTON GROUP Ltd Buys 10,655 Shares of Eli Lilly and Company $LLY

WINTON GROUP Ltd boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 394.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 13,355 shares of the company’s stock after purchasing an additional 10,655 shares during the quarter. WINTON GROUP Ltd’s holdings in Eli Lilly and Company were worth $14,352,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Viewpoint Capital Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $221,000. Arsenal Capital Advisors LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $1,150,000. FLC Capital Advisors boosted its position in Eli Lilly and Company by 2.3% during the fourth quarter. FLC Capital Advisors now owns 1,167 shares of the company’s stock valued at $1,254,000 after purchasing an additional 26 shares in the last quarter. Parallel Advisors LLC boosted its position in Eli Lilly and Company by 2.6% during the fourth quarter. Parallel Advisors LLC now owns 29,966 shares of the company’s stock valued at $32,204,000 after purchasing an additional 749 shares in the last quarter. Finally, TruNorth Capital Management LLC boosted its position in Eli Lilly and Company by 61.1% during the fourth quarter. TruNorth Capital Management LLC now owns 625 shares of the company’s stock valued at $672,000 after purchasing an additional 237 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on LLY shares. Bank of America raised their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Daiwa Securities Group raised their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Rothschild & Co Redburn raised their price target on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Jefferies Financial Group raised their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a report on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,133.15 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market cap of $1.07 trillion, a PE ratio of 40.25, a P/E/G ratio of 1.23 and a beta of 0.53. The business has a 50-day simple moving average of $974.59 and a two-hundred day simple moving average of $1,013.04. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,166.29.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.During the same quarter last year, the company earned $3.34 earnings per share. The company’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.